NLS Pharma Group’s lead compound, NLS-1 (mazindol), more than halved a common measure of attention deficit hyperactivity disorder (ADHD) symptoms in 55 percent of treated adults vs. 15.8 percent of placebo-treated subjects in a randomized phase II trial. Read More
DUBLIN – Inthera Bioscience AG raised CHF10.5 million (US$10.8 million) in a series A round to further its development of small-molecule inhibitors of protein-protein interactions, one of the most important frontiers in drug discovery. Read More
A new Chinese study’s findings suggest Adriamycin-based chemotherapy may simulate cancer stem cells (CSCs) through transcription factor signaling activation, but that such signaling is inhibited by statins. Reported in the May 25, 2017, online edition of Stem Cell Reports, the results may be important in designing new osteosarcoma treatment regimens. Read More
For those working in the area of cancer today, it’s impossible to attend a meeting or scientific session without hearing about genetically targeted therapies or efforts in the increasingly hot immuno-oncology space. But a small firm out of Boston has a different view when it comes to cancer therapy. Read More
The EMA and the European Commission Wednesday published the first in a series of guidances to help drug companies prepare for the U.K.’s withdrawal from the EU. Read More
Immunovaccine Inc., of Halifax, Nova Scotia, said it entered a bought deal financing agreement to sell about 7.7 million common shares at a price of C$1.30 (US97 cents) per share for gross proceeds of about C$10 million. Read More
Alnylam Pharmaceuticals Inc., of Cambridge, Mass. won FDA breakthrough status for givosiran (ALN-AS1), the company’s investigational RNAi therapy targeting aminolevulinic acid synthase 1 for the prophylaxis of attacks in patients with acute hepatic porphyria. Read More
Novartis AG, of Basel, Switzerland, said findings from a pilot study of CTL-119, a humanized CD19-directed CAR T-cell therapy, in combination with BTK inhibitor Imbruvica (ibrutinib, Abbvie Inc./Johnson & Johnson) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), who had been taking ibrutinib for at least six months and who were not in complete remission, showed that eight of nine evaluable patients had no signs of CLL in their bone marrow at three months. Read More
